Introduction
============

Bioinformatics is a scientific field that has gained popularity worldwide. In particular, bioinformatics represents a multidisciplinary field of biology, information technology and mathematics, and harnesses the power of the Internet. Advancements in molecular biology technologies have led to the emergence of extremely large datasets, commonly known as "big data." It is increasingly difficult to manage biological and chemical data with traditional methods because of both the larger size and increasing complexity of these datasets. Novel computing technologies and perspectives applying effective bioinformatics methods are required to accurately manage various data sources.

Colorectal cancer (CRC) is one of the leading cancers worldwide ([@ref-12]; [@ref-13]). Several studies have revealed that CRC screening can detect and reduce its progression toward an advanced disease stage, which leads to better overall survival. In the past, traditional CRC screening methods have included fecal blood testing, flexible colonoscopy and barium enema X-ray ([@ref-20]). However, these tests are conducted in clinical practice with some limitations, such as variable sensitivity (37--80%) and potential die *t*-test interactions ([@ref-31]). Therefore, new biomarkers have been developed for the detection of CRC to improve the sensitivity and specificity of detection ([@ref-8]).

Microarray assays can be applied to acquire information on thousands of genes simultaneously and provide clear insights into genomic alterations related to the process of colorectal carcinogenesis, tumor growth, and metastasis. The results of microarray assays enable the identification of gene signatures for diagnosis, molecular characterization, prognostic analysis, and treatment prediction ([@ref-31]).

Nevertheless, studies have revealed that the application of microarray analysis in clinical practice still faces certain challenges. First, there is a general lack of concordance between the results obtained from individual studies because of technique-related variations in sample collection and different types of platforms and methods ([@ref-6]). Second, there is a shortage of large-scale studies because of the relatively small number of available patient samples, which leads to reduced statistical power ([@ref-7]). Third, identifying data that would be the most informative and useful for the development of reliable clinical applications has been challenging ([@ref-31]; [@ref-8]; [@ref-10]; [@ref-12]; [@ref-13]).

To overcome these challenges, one approach is to use the online Gene Expression Omnibus (GEO) database, which can help increase the sample size, heterogeneity of a sample, and statistical power. Several methods can be applied to analyze variations in gene expression between colorectal tumors and normal mucosa tissues to screen for significant cancer-related genes ([@ref-11]; [@ref-12]; [@ref-13]). In this study, we followed the Prediction Analysis for Microarrays (PAM) method to screen for significant CRC-associated genes that could be used as predictive markers for early cancer detection. Furthermore, Gene Ontology (GO) pathways and Gene Set Enrichment Analysis (GSEA) were employed to confirm the function and association of the candidate genes with the risk of CRC.

Methods
=======

Microarray data sources
-----------------------

Microarray data were collected from the online GEO database between September 2011 and March 2014.

In this study, we searched the GEO database of the National Center for Biotechnology Information using the keywords "colon cancer," "human \[organism\]," and "expression profiling by array \[dataset type\]."

The three main inclusion criteria for our data were as follows: (1) frozen tissue sections collected from primary CRC, normal human colorectal mucosa, or hepatic metastases in patients with CRC; (2) the microarray platform contained single-color, whole-genome gene chips from Affymetrix; and (3) the data were presented as the mean gene expression level. The exclusion criteria were as follows: (1) data collected from cultured cell lines or other *in vitro* assays; (2) datasets lacking the original gene expression levels; and (3) sub-datasets with redundancy ([Fig. 1](#fig-1){ref-type="fig"}).

![Process of pooling the 11 microarray gene expression datasets.\
GEO, Gene Expression Omnibus; GSE, GEO series.](peerj-05-3003-g001){#fig-1}

Based on these criteria, a total of 401 GEO series (GSE) datasets were excluded; therefore, 11 public microarray datasets were used for the analysis ([GSE18088](GSE18088), [GSE20916](GSE20916), [GSE21510](GSE21510), [GSE23878](GSE23878), [GSE29623](GSE29623), [GSE31595](GSE31595), [GSE32323](GSE32323), [GSE33113](GSE33113), [GSE35144](GSE35144), [GSE37892](GSE37892), and [GSE49355](GSE49355)), which included 717 tumor cases and 134 normal mucosa control samples ([Table 1](#table-1){ref-type="table"}).
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###### GSE datasets included in our study.
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  GSE              Tissue   Total numbers   Total number of genes on chips   Type of gene chips   
  ---------------- -------- --------------- -------------------------------- -------------------- ----------------
  [18088](18088)   53                       53                               33727                HG-U133_Plus_2
  [20916](20916)   115      30              145                              33727                HG-U133_Plus_2
  [21510](21510)   105      43              148                              33727                HG-U133_Plus_2
  [23878](23878)   59                       59                               33727                HG-U133_Plus_2
  [29623](29623)   65                       65                               33727                HG-U133_Plus_2
  [31595](31595)   37                       37                               33727                HG-U133_Plus_2
  [32323](32323)   17       17              34                               33727                HG-U133_Plus_2
  [33113](33113)   90       6               96                               33727                HG-U133_Plus_2
  [35144](35144)   27                       27                               33727                HG-U133_Plus_2
  [37892](37892)   130                      130                              33727                HG-U133_Plus_2
  [49355](49355)   19       38              57                               14713                HG-U133A

In addition, we included microarray datasets obtained from our laboratory and published by [@ref-10] ([GSE4107](GSE4107), [GSE4183](GSE4183), [GSE8671](GSE8671), [GSE9348](GSE9348), [GSE10961](GSE10961), [GSE13067](GSE13067), [GSE13294](GSE13294), [GSE13471](GSE13471), [GSE14333](GSE14333), [GSE15960](GSE15960), [GSE17538](GSE17538), and [GSE18105](GSE18105)), which included 519 adenocarcinoma cases and 88 normal mucosa control cases.

Preprocessing of microarray data
--------------------------------

To lower the background noise of the microarray chips related the gene expression levels, data preprocessing was performed using the standard GC Robust Multi-Array Average (GCRMA) method. In addition, we also used the R language software package to conduct our study ([@ref-12]; [@ref-13]). This analysis of gene expression levels used the median probe expression level based on the skewed distribution of the expression levels of the probe.

[@ref-2] proposed applying the GCRMA method over the conventional Robust Multichip Average (RMA) method. RMA analysis is performed to adjust the affinity among the nucleotides based on the different binding strengths between GC and AT provided by the Affymetrix Console. The RMA method is designed for processing Affymetrix chips. The microarrays were first preprocessed for within-study normalization using the GCRMA method, and then the calculated gene levels were estimated before the different studies were combined, while retaining only the genes that were available on all the microarrays. Next, the same preprocessing procedure was performed for between-study normalization ([@ref-12]; [@ref-13]).

The Affymetrix chips used in the datasets were HG-U133A and HG-U133-Plus-2, which accounted for 14,713 and 33,727 of the corresponding number of genes in our study, respectively. To obtain the expression levels of the 14,698 genes, 11 datasets were merged. Next, quantile normalization was conducted on all gene expression values ([@ref-2]).

The PAM model
-------------

The PAM method utilizes nearest shrunken centroid methodology. The use of the PAM method may be of crucial importance for reducing not only signal noise but also the false discovery rate (FDR), which leads to the selection of the best candidate gene set ([@ref-27]). The PAM method is preferred because it performs better with fewer genes ([@ref-27]; [@ref-12]; [@ref-13]). [@ref-35] reanalyzed the leukemia microarray data of [@ref-17] and confirmed 43 of the 96 genes in the microarray data using the PAM method. The results were comparable with the results of [@ref-23], which were obtained using the ANN method. Furthermore, the FDR was reduced from 4 to 2 over 34 classifications.

Functional pathway analysis
---------------------------

The use of pooled GEO studies was secondary because only the microarray data were available. Previous studies have proposed that testing 55 genes in any experimental model is beneficial for colon cancer biology ([@ref-8]; [@ref-10]; [@ref-12]; [@ref-13]). Therefore, in the present study, functional pathways related to the tumorigenesis of CRC were evaluated using GSEA software version 2.07. The GSEA MSigDB resource provides a collection of annotated gene sets based on different sources of information, including gene ontology, pathways, and motifs ([@ref-6]). Using the GSEA MSigDB resource, we analyzed the 14,698 genes that were identified by examining the expression values between the normal and tumor tissues.

Results
=======

The PAM analysis identified 10 significant candidate genes at least once after 100 repeated samplings (*ABCG2, AQP8, SPIB, CA7, CLDN8, SCNN1B, SLC30A10, CD177, PADI2* and*TGFBI)* ([Table 2](#table-2){ref-type="table"}). Three of these genes---*ABCG2, AQP8, and SPIB*---were identified in all 100 repeated samplings. *CA7* was identified 99 times, *CLDN8* 89 times, *CNN1B* 62 times, *SLC30A10* 29 times, *CD177* five times, *PADI2* two times and *TGFBI* two times. The more frequently a gene was identified in this analysis indicates its increased importance in CRC.
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###### The centroid scores and frequency of the colorectal cancer genes in the 100 repeated samplings using the PAM method.
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                   CRC centroid score   NOR centroid score   Diff score (Max)                                                       
  ---------- ----- -------------------- -------------------- ------------------ --------- ---------- ---------- --------- --------- --------
  ABCG2      100   −0.023285            0.005258             −0.0121            −0.0406   0.183034   0.041345   0.3191    0.0949    0.3597
  AQP8       100   −0.024511            0.005812             −0.0096            −0.0372   0.192729   0.045658   0.2925    0.0754    0.3297
  SPIB       100   −0.034727            0.004733             −0.0207            −0.0456   0.273003   0.037222   0.3582    0.1625    0.4038
  CA7        99    −0.051488            0.005233             −0.0429            −0.0666   0.404711   0.041172   0.5239    0.3369    0.5905
  CLDN8      89    −0.010152            0.004605             −0.0015            −0.026    0.079792   0.036207   0.2044    0.0118    0.2304
  SCNN1B     62    −0.004138            0.00235                                 −0.0098   0.032498   0.018485   0.0771    0.0002    0.0869
  SLC30A10   29    −0.004566            0.002946             −0.0003            −0.0102   0.035979   0.023184   0.0804    0.0024    0.0906
  CD177      5     −0.00254             0.002319             −0.0004            −0.0051   0.02006    0.018175   0.0403    0.0034    0.0454
  PADI2      2     −0.00265             0.001768             −0.0014            −0.0039   0.0208     0.013859   0.0306    0.011     0.0345
  TGFBI      2     0.00045              0.000354             0.0007             0.0002    −0.0033    0.002687   −0.0014   −0.0052   0.0059

**Notes.**

CRCcolorectal cancer tissueNORnormal tissue

Furthermore, genes with a higher absolute centroid value were of greater importance in the CRC risk analysis because this value indicated a better ability to differentiate between cancer and normal tissues. *CA7* had the highest centroid value (0.5905), followed by *SPIB* (0.4038) and *ABCG2* (0.3597). *TGFBI* had the lowest centroid value (0.0059).

The number of genes identified using the PAM method is a good indicator of the candidate genes that correlate with CRC. The lowest threshold of the misclassification error rate to distinguish CRC from normal colon tissues was 14 of 100 repeated samples ([Fig. 2](#fig-2){ref-type="fig"}). Furthermore, only six genes were required to distinguish CRC from normal colon tissues. The average accuracy rate of the model was 95% (standard deviation = 0.44), and the validation accuracy rate of the model was 95.2% (standard deviation = 1.33). The average number of significant genes obtained from the selection was six ([Fig. 3](#fig-3){ref-type="fig"})

![(A) The lowest threshold between the normal tissue and colorectal tumors tissue is 14; (B) The number of needed genes is between four and eight genes.](peerj-05-3003-g002){#fig-2}

![PAM model accuracy rates.\
The average PAM model accuracy rate was 95% (SD = 0.44). The average validation accuracy rate was 95.2% (SD = 1.33). The average number of significant genes was 5.9.](peerj-05-3003-g003){#fig-3}

The resulting 10 significant genes from the 100 repeated samplings were derived from Gene Ontology analysis. In the molecular function Gene Ontology category, *SLC30A10*, *ABCG2*, and *AQP8* are related to material transportation, *SPIB* and *TGFBI* are related to receptor binding, and the other genes are related to enzyme activities. In the biological process category, *SCNN1B* and *TGFBI* are specifically related to sensory perception and organ development. In the cellular component category, only *CLDN8* localizes to the plasma membrane, and the remaining genes were not annotated ([Table 3](#table-3){ref-type="table"}).
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###### The GO terms, GO molecular function, GO biological process, GO cellular component of the 10 significant colorectal cancer genes.
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       GO terms                                                GO molecular function                                               GO biological process                                         GO cellular component
  ---------- ------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------- -----------------------
  CA7        Carbonic anhydrase 7                                    Hydro-lyase activity                                                Metabolic process                                             

  SCNN1B     Amiloride-sensitive sodium channel subunit beta         Ion channel activity                                                Sensory perception of taste\                                  
                                                                                                                                         Sensory perception of pain\                                   
                                                                                                                                         Cation transport\                                             
                                                                                                                                         Regulation of biological process                              

  SPIB       Transcription factor Spi-B                              Sequence-specific DNA binding transcription factor activity\        B cell mediated immunity\                                     
                                                                     Receptor binding                                                    Macrophage activation\                                        
                                                                                                                                         Transcription from RNA Polymerase II promoter\                
                                                                                                                                         Cell cycle\                                                   
                                                                                                                                         Cell communication\                                           
                                                                                                                                         Endoderm development\                                         
                                                                                                                                         Mesoderm development\                                         
                                                                                                                                         Hemopoiesis\                                                  
                                                                                                                                         Cellular defense response\                                    
                                                                                                                                         regulation of transcription from RNA polymerase II promoter   

  CD177      CD177 antigen                                                                                                                                                                             

  SLC30A10   Zinc transporter 10                                     Transmembrane transporter activity                                  Cation transport                                              

  TGFBI      Transforming growth factor-beta-induced protein ig-h3   Receptor binding                                                    Cell communication\                                           
                                                                                                                                         Cell--matrix adhesion\                                        
                                                                                                                                         Visual perception\                                            
                                                                                                                                         Sensory perception\                                           
                                                                                                                                         Mesoderm development\                                         
                                                                                                                                         Skeletal system development\                                  
                                                                                                                                         Muscle organ development                                      

  PADI2      Protein-arginine deiminase type-2                       Hydrolase activity                                                  Cellular protein modification process                         

  ABCG2      ATP-binding cassette sub-family G member 2              ATPase activity, coupled to transmembrane movement of substances\   Lipid metabolic process\                                      
                                                                     Transmembrane transporter activity                                  Lipid transport                                               

  CLDN8      Claudin-8                                                                                                                   Cellular process                                              Plasma membrane\
                                                                                                                                                                                                       Cell part

  AQP8       Aquaporin-8                                             Transmembrane transporter activity                                  Transport                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

[@ref-10] verified and compared 3 gene expression profiles for CRC using 12 GEO-online microarray databases. In addition, the authors merged three profiles and obtained a 4th profile with higher accuracy. The results of dry-lab analyses must be verified by wet-lab experiments, and conversely, the results of wet-lab experiments must be explored in dry-lab analyses. We believe that more precise experiments are needed to investigate the genes selected in the present study as in our previous publications ([@ref-8]; [@ref-10]; [@ref-12]; [@ref-13]; [@ref-25]; [@ref-26]). The lack of dry-lab analyses may be a limitation but also provides opportunities for complete external validation in future studies. For example, we were the first to report that carbonic anhydrase VII (CA7) expression plays an initiating but not progressive role in CRC ([@ref-13]) Subsequently, two studies ([@ref-21]; [@ref-43]) verified the role of CA7 by western blot and immunohistochemistry analyses as well as qRT-PCR analyses of clinical samples including colorectal paraffin-embedded (FFPE) tissue. Recent studies have reported that miRNAs often function as tumor suppressors or oncogenes. miRNAs related to carcinogenesis are regarded not only as diagnostic and prognostic biomarkers but also as therapeutic targets. The miR-200 family is related to TGF-*β*2 and functions in the suppression of metastasis ([@ref-26]).

Furthermore, four genes, ABCG2, PADI2, CA7, and TGFBI, have been verified in previous studies as potentially correlated with colorectal cancer. [@ref-38] conducted a study of resected primary tumor specimens from 189 patients and evaluated the expression of the ABCG2 protein and drug sensitivity to SN-38 (an active metabolite of irinotecan). They also analyzed progression-free survival (PFS). Of the tumors, 60% showed higher ABCG2 expression and greater resistance to SN-38. In addition, the risk of resistance was increased by 12-fold in these tumors. PFS was lower in patients with higher expression of ABCG2. These results demonstrated that ABCG2 is a useful predictive biomarker of resistance to irinotecan and survival.

[@ref-5] conducted a study of PADI2 expression in 98 cancer patients and 50 donors without cancer as a control group. PADI2 expression was lower or even absent in CRC. In addition, a low level of PADI2 expression in the colon mucosa was also observed in patients with ulcerative colitis. The authors concluded that a lower PADI2 expression level was associated with poorer prognosis.

[@ref-43] performed real-time PCR, western blot, and immunohistochemistry analyses to evaluate the level of CA7 expression in CRC samples. Their study included two groups: a training cohort group of 228 patients to evaluate pathological features and a validation group of 151 patients from different cities in China. The authors used Kaplan--Meier and Cox proportional regression analyses to evaluate the relationships between CA7 expression and patient survival. The results showed that decreased gene expression levels of CA7 were related to disease progression. Therefore, CA7 can predict poor prognosis in patients with CRC and early-stage tumors.

[@ref-44] conducted a study of TGFBI in 115 patients using immunohistochemistry methods. Most of the TGFBI was localized in the cytoplasm in cancer tissues. High expression levels of TGFBI in the cytoplasm were related to lymph node metastasis and distant metastasis. In addition, high TGFBI was related to poor prognosis. In other words, TGFBI can be regarded as an indicator of poor prognosis in patients with CRC. Verification of our other six candidate genes in future studies is critically important.

Three genes---*ABCG2 AQP8* and *SPIB*---were identified by the PAM model to have significantly different expression levels between CRC and normal colon mucosa tissues from 100 repeated samplings. *ABCG2* is a half-transporter of the G subfamily of ATP-binding cassette transporter (ABC transporter) genes and is known to confer multidrug resistance. The mechanism of *ABCG2*-mediated multidrug resistance is related to the JNK1/c-Jun (c-Jun N-terminal kinase) signaling pathway ([@ref-41]). [@ref-1] revealed that the mRNA expression of *ABCG2* was decreased in cancer tissues. These findings underscore the importance of ABC transporters in the early steps of carcinogenesis and suggest that tumor formation might be related to epithelial barrier dysfunction. In addition, [@ref-22] proposed that ABCG2 could be utilized as a prognostic biomarker. Their results indicated that patient survival after operation correlated with the expression of membranous ABCG2 tumors. Therefore, the detection of ABCG2 can not only identify a possible risk of colorectal cancer risk but also support survival prediction and treatment strategies.

SPIB is an ETS family transcription factor that is associated with the putative oncogene product PU.1. Furthermore, ETS transcription factors are involved in malignant transformation of cells and therefore are possible targets for cancer therapy ([@ref-33]; [@ref-32]). [@ref-34] revealed that SPIB expression is a novel indicator of poor prognosis in patients with diffuse large B-cell lymphoma and mediates apoptosis through the PI3K-AKT pathway. Furthermore, [@ref-19] reported that high *SPIB* and *KI-67* mRNA expressions levels were associated with poor survival in patients with hepatocellular carcinoma. Therefore, SPIB may be related to not only carcinogenesis but also prognosis in colorectal cancer. Nevertheless, further studies are required to validate these findings.

AQP8 is a member of the aquaporin (AQP) family and facilitates water transport across the cell plasma membrane. Recent studies have revealed that AQP expression in tumors is related to cell extravasation, invasion and metastases ([@ref-43]). However, the clinical importance of AQP8 in colon cancer remains undetermined. [@ref-40] reported two phenomena. The first is that AQP8 is not expressed in patients with colorectal carcinoma. The second is that AQP5 expression is associated with cancer stage, pathology differentiation, and lymph node metastasis. These findings suggest that decreased AQP8 expression and increased AQP5 expression might be related to oncogenesis.

CA7 is a member of the carbonic anhydrases gene family, which has been proposed to be related to the pathogenesis of human cancers. Indeed, CA7 is associated with poor prognosis and disease progression, particularly in the early stages of colon cancer. As a result, decreased expression of CA7 may be a poor prognostic indicator of CRC. In contrast, [@ref-3] reported that upregulation of CA7 expression was indicative of poor prognosis in patients with astrocytomas ([@ref-39]).

CLDN8 is a member of the family of claudins, which play a role in tumorigenesis through alterations in cell interactions. In CRC tissues, CLDN1 and CLDN2 were upregulated. In contrast, CLDN5, 8, 15, and 23 were downregulated in CRC ([@ref-18]; [@ref-4]).

SLC30A10 is related to the methylation epigenotype and molecular genesis of CRC ([@ref-42]). In addition, SCNN1B is associated with hypermethylation in CRC. [@ref-30] proposed that tumorigenesis results from epigenetic changes, including hypermethylation ([@ref-24]). Guillaume et al. reported that SCNN1B is hypermethylated in renal cell carcinoma and is considered a new epigenetic marker for clear cell kidney carcinoma, which suggests it is a viable diagnostic test of urine or blood samples.

CD177 has been proposed as a stem cell factor receptor. [@ref-14] reported that tumor stem cells likely contribute to the metastatic potential of cancers and may be responsible for chemotherapy resistance and induction of dormancy in tumors. Therefore, the detection, isolation, and characterization of tumorigenesis remain a challenge in cancer treatment strategies. In addition, [@ref-36] proposed that CD177 regulates tumor cell adhesion and migration in gastric cancer. In particular, increased expression of CD177 in gastric cancer is a prognostic factor for survival. PADI2 is a member of the PAD family, which is commonly associated with abnormal pathological properties of inflammation ([@ref-9]). [@ref-29] reported that dysregulation of PADI activity is associated with several diseases, such as chronic obstructive pulmonary disease, rheumatoid arthritis and cancer. Furthermore, the authors revealed that PADI2 might play an important role in cancer progression and may be a potential biomarker for breast cancer. Transforming growth factor-beta-induced (TGFBI) has been reported to be a linker protein. Numerous human cancers exhibit high levels of *TGFBI* gene expression. Furthermore, high TGFBI protein expression is an indicator of poor prognosis in patients with CRC ([@ref-44]). [@ref-37] also reported that the expression of TGFBI is characteristic of liver metastasis in CRC.

The present study identified certain genes associated with CRC from pooled microarray datasets from several studies. Compared with previous studies, we used a similar method but found different gene expression profiles associated with CRC. Because our studies complement each other, the compatibility of the results is more impressive. These genes were found to be involved in the regulation of upstream, midstream, and downstream molecular signaling pathways, and their expression could be explained by gene collinearity because the genes were highly correlated. However, studies have reported that DNA microarray data might have collinearity problems among the gene expression data ([@ref-28]; [@ref-15]). Future studies should confirm the collinearity of these genes.

In a large study of cancer, Andrew et al. analyzed the gene expression signatures of approximately 18,000 human tumors across 39 malignancies. However, our study was more specific for colorectal cancer and provided a detailed examination of survival and carcinogenesis of one cancer type. The prior study provided a wide screening of all types of cancers, whereas the latter is more specific and concentrated on the genes associated with colorectal cancer ([@ref-16]).

Future studies should clarify the reliability of the gene signatures observed in this study for predicting CRC risk. Furthermore, the characteristics of the candidate genes identified in this study merit further investigation using molecular biology methods, such as those involving epigenetics and genetics, DNA methylation, mRNA expression levels, mRNA interactions, and associated biochemical pathways.

Our method of investigation is not without limitations. The first limitation is that the datasets were collected from several research studies; this approach has the benefit of an increased sample size but may increase the heterogeneity due to the different types of research designs. The second limitation is that we did not identify discrepancies in CRC-related variables or variables influencing the survival of patients with CRC among the different studies. Our analysis of pooled microarray studies published in recent years revealed that several international teams have proposed different CRC gene expression profiles covering diverse candidate and verified genes, with less than 25% similarity, despite intra-observational analyses performed using various bioinformatics techniques. These discrepancies may be attributable in part to sampling variations that are not eliminated by bootstrapping, but statistical collinearity within the same pathway or associated network of gene-gene interactions is likely a more important factor and requires further study.

Conclusions
===========

Using the appropriate bioinformatics tools and the PAM method to obtain 100 repeated samplings, we identified 10 candidate genes that are significantly associated with CRC (*ABCG2 AQP8*, *SPIB*, *CA7*, *CLDN8*, *SCNN1B*, *SLC30A10*, *CD177, PADI2* and *TGFBI)*. On average, six genes were selected by the PAM model to effectively classify normal and CRC tissues, and the average accuracy rate was 95%. We hope that these results will provide the basis for new research projects in clinical practice to rapidly assess colorectal cancer risk using microarray gene expression analysis.
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